Lipid nucleotide analog prodrugs for oral administration
AssigneeNeXstar Pharmaceuticals, Inc.
InventorsKarl Y. Hostetler, Raj Kumar, Nagarajan C. Sridhar
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeXstar Pharmaceuticals, Inc.
InventorsKarl Y. Hostetler, Raj Kumar, Nagarajan C. Sridhar
Estimating the term…
The oral delivery of many classes of drugs is facilitated by converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn- glycero-3-phosphate derivatives. The method confers the ability to be absorbed through the digestive tract to drugs that are not orally bioavailable in the non-derivatized state, and enhances the effectiveness of drugs that are poorly absorbed or rapidly eliminated. The method provides orally bioavailable lipid prodrugs of pharmaceutical compounds having diverse physiological activities, including anticancer and antiviral agents, anti-inflammatory agents, antihypertensives and antibiotics. Potency of the lipid prodrugs is comparable to that of the corresponding non-derivatized drugs.
A method of enhancing the pharmacokinetic properties of an orally administered drug, comprising:
A lipid prodrug of the formula ##STR4## wherein R is a substitute or unsubstituted, saturated or unsaturated, straight or branched chain, or cyclic C.sub.1 to C.sub.24 alkyl group, covalently linked to the glycerol moiety in an ether linkage;
Dependencies are inferred from the claim text.